Peptide news
These are the updates on this site, newest first. Each one points at a page that cites the study, the label, or the regulator letter. The list is a log, not a wire service, and it is not medical advice. The map of the library is start here. How a claim gets graded is methods.
-
HHS filed a draft interim enforcement-discretion policy for six peptides, including BPC-157, TB-500, and MOTS-c. FDA has not approved them, and the 503A Bulks List is unchanged. The legal-status page has the conditions. A research-use-only label is still its own explainer.
-
Mounjaro and Zepbound are the same molecule on two labels. The comparison includes the July 2026 Mounjaro label. The Canadian generic semaglutide notices are on their own page. The tablet file is the Wegovy pill. What a research-use-only line does is the explainer.
-
Foundayo is on the approved list. Retatrutide is not. The GLP-1 drugs list and the drugs still in trials keep those records apart. Compounded tirzepatide is on its own page.
-
Retatrutide is still not approved. Lilly plans a US submission in the first quarter of 2027. The retatrutide FDA approval article
-
TRIUMPH-1 was published in the New England Journal of Medicine: 25.0% average weight loss at 80 weeks with retatrutide, versus 3.9% with placebo. The TRIUMPH results
-
FDA warning letters to online peptide sellers said a research-use-only line did not control when the sites showed human use. What the label means
-
In July 2026 FDA staff proposed that BPC-157 stay off the 503A Bulks List. FDA has not posted committee minutes, and no proposed rule adding it was found as of October 15, 2026. Is BPC-157 banned for athletes?